MVC-COV1901(S protein with adjuvant)

BIOLOGICAL4 trials

Sponsors

Medigen Vaccine Biologics Corp.

Conditions

Covid19 Vaccine

Phase 2

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adult

CompletedNCT04695652

Medigen Vaccine Biologics Corp.Covid19 Vaccine

Start: 2020-12-30End: 2021-10-29Updated: 2022-01-31

A Study to Evaluate MVC-COV1901 Vaccine Against COVID-19 in Adolescents

CompletedNCT04951388

Medigen Vaccine Biologics Corp.Covid19 Vaccine

Start: 2021-07-22End: 2022-03-21Updated: 2022-04-20

A Study o Evaluate the Safety, Tolerability, and Immunogenicity of MVC-COV1901, CT-COV-21 Sub-study

CompletedNCT05038618

Medigen Vaccine Biologics Corp.Covid19 Vaccine

Start: 2021-08-02End: 2022-03-11Updated: 2022-06-13

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of COVID-19 Vaccine, CT-COV-21 Extension Study

CompletedNCT05048849

Medigen Vaccine Biologics Corp.Covid19 Vaccine

Start: 2021-07-19End: 2022-04-12Updated: 2022-08-24

Related Papers

A Retrospective Study of the Safety and Immunogenicity of MVC-COV1901 Vaccine for People Living with HIV

Vaccines2022-12-216 citations

Safety and immunogenicity of SARS-CoV-2 vaccine MVC-COV1901 in Taiwanese adolescents: a randomized phase 2 trial

npj Vaccines2022-12-1614 citations

Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.

2021-10-13110 citations

Safety and Immunogenicity of CpG 1018 and Aluminium Hydroxide-Adjuvanted SARS-CoV-2 S-2P Protein Vaccine MVC-COV1901: A Large-Scale Double-Blind, Randomised, Placebo-Controlled Phase 2 Trial

TUScholarShare (Temple University)2021-08-081 citations

Safety and immunogenicity of a Recombinant Stabilized Prefusion SARS-CoV-2 Spike Protein Vaccine (MVC-COV1901) Adjuvanted with CpG 1018 and Aluminum Hydroxide in healthy adults: A Phase 1, dose-escalation study.

2021-06-2651 citations